Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, ...
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal ...
HealthInvest showcased ASX-listed healthcare companies where scientific innovation, commercial opportunity and patient outcomes align.
As part of the campaign, AKF has enhanced its webpage on FSGS with expanded information on diagnosis, treatment options and types of FSGS. AKF also created accompanying digital guides for patients on ...
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.
GlobalData on MSN
Otsuka’s Voyxact preserves kidney function at 12 months
Otsuka’s Voyxact was granted accelerated approval from the FDA in November 2025 based on nine-month data.
A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results